Avalo Therapeutics, Inc. Common Stock

AVTXNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
19.37 USD
↗ 1.49 (8.33%)AT CLOSE (11:59 AM EDT)
18.39
↘ 0.98 (5.09%)
POST MARKET (AS OF 05:03 PM EDT)
Post Market
AS OF 05:03 PM EDT
18.39
↘ 0.98 (5.09%)
🟢Market: OPEN

Shares of Avalo Therapeutics, Inc. Common Stock (AVTX) are trading at $18.56. AVTX shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$17.79
High?$19.49
Low?$17.54
Prev. Close?$17.88
Volume?1.2M
Avg. Volume?1.8M
VWAP?$18.82
Rel. Volume?0.68x
Bid / Ask
Bid?$16.59 × 100
Ask?$22.45 × 100
Spread?$5.86
Midpoint?$19.52
Valuation & Ratios
Market Cap?939.9M
Shares Out?52.6M
Float?21.2M
Float %?86.6%
P/E Ratio?N/A
P/B Ratio?13.76
EPS?-$1.61
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Themes
Biotech - Drug Development›Immunology & Autoimmune
Employees
33
Market Cap
939.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.avalotx.com
Listed
2015-11-13
Address
1500 LIBERTY RIDGE DRIVE
WAYNE, PA 19087
Phone: 410-522-8707
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
13
Piotroski F-Score?0/9Weak
Altman Z-Score?9.62Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?57.99%Squeeze Risk
Short Interest?12.3M
Days to Cover?4.3
Free Float21.2M
Avg Daily Volume2.9M
Settlement Date2026-06-30
Financial Health
Current Ratio?7.65Strong
Quick Ratio?7.65Strong
Cash Ratio?2.15Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
14
13.76HIGH▾
P/S?
Peers
100
S&P
3
15,930.04HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-11.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
15,506.52HIGH▾
Returns & Efficiency
ROE?
S&P
3
-124.0%WEAK▾
ROA?
S&P
3
-84.8%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$914.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist